20 articles
Demethyleneberberine, derived from traditional Chinese medicine, significantly reduced lung scarring by targeting NLRP3 inflammasome and EMT in mice.
Natural flavonoid fisetin activates mitophagy and xenophagy pathways to restrict intracellular Salmonella growth in immune cells.
Historical analysis reveals how colchicum has remained a cornerstone gout treatment for over 2,000 years of medical practice.
Scientists reveal how a measles antiviral also blocks Nipah virus and use structural insights to engineer more potent next-generation inhibitors.
New research reveals how hepatitis B virus hijacks cellular machinery to suppress interferon signaling and evade immune detection.
GlaxoSmithKline tests a novel NS5B inhibitor across four dose groups in chronic HCV patients, evaluating safety and short-term antiviral activity.
Genetic variants of Epstein-Barr virus influence how well MS patients respond to interferon therapy, enabling personalized treatment.
Senescent cells drive cyst growth in ADPKD, and targeting them with senolytics or the aldose reductase inhibitor epalrestat delays disease progression.
New research reveals efgartigimod reshapes B-cell populations in myasthenia gravis, inducing regulatory plasma cells linked to clinical improvement.
Dying cancer cells release GPX4 protein that prevents immune system activation, revealing new immunotherapy targets.
A randomized phase 2 trial finds CM313 achieves 83% response rate vs 20% placebo in treatment-resistant immune thrombocytopenia.
Updated EULAR recommendations provide comprehensive management strategies for this complex autoimmune condition affecting multiple organs.
Researchers identified specific lupus patient subgroups who respond dramatically better to baricitinib using gene expression analysis.
Breakthrough therapy targeting B cells demonstrates significant improvement in lupus symptoms with sustained benefits over one year.
Systematic uric acid monitoring and treatment achieved 64% better remission rates than waiting for symptoms to guide therapy.
Whole genome sequencing of 7,339 Chinese participants uncovers novel genetic variants affecting serum uric acid, opening doors for precision therapies.
New research reveals JAK inhibitors significantly increase hearing loss when combined with aminoglycoside antibiotics.
Combining targeted therapies may help patients with severe hidradenitis suppurativa who don't respond to standard treatments.
Phase I trial tests selective JAK3 inhibitor with improved safety profile compared to existing treatments for inflammatory conditions.
JAK inhibitors outperform traditional treatments for rheumatoid arthritis but carry cardiovascular and infection risks.
